

Efficacy and safety of ALLERGIKA®-Facial Cream MED by IGA/ PGA evaluation of the symptoms redness, scaling and skin dryness

(Arenberger et al., 2021, publication in preparation)




Study center	Dermatology Clinic of Charles University in Prague, Šrobárova 50, 100 34 Prague 10, Czech Republic
Head of Study	Prof. Dr. Petr Arenberger
Objective	Efficacy and tolerability of ALLERGIKA®-Facial Cream MED in patients with facial eczema. The significance of the difference between the IGA score and the PGA score at the initial and subsequent visits is tested. Patient satisfaction with the product used.
Target parameters	1. Symptoms: Redness, scaling, skin dryness 2. Score: Investigator Global Assessment (IGA) 3. Score: Patient Global Assessment (PGA)
Implementation	1. Doctor and patient assess the symptoms of redness, dryness of the skin and the presence of scaling in the facial area 2. Determination of the IGA and PGA score at 0d, 7d and 21d 3. Assessment of patient satisfaction with the monitored product in relation to the product characteristics
Study product	ALLERGIKA®-Facial Cream MED
Study design	Prospective, uncontrolled observational study
Participants	32 male and female patients with atopic (50%), irritant (12.5%), and contact-allergic (37.5%) facial eczema between 18 and 65 years of age
Study period	3 weeks
Application area	Facial area

Results

1. The symptoms of eczema decreased statistically significantly by 72%. The appearance-free intervals could be significantly extended.
2. The extraordinarily high effectiveness is based on water-in-oil galenic, as Wohlrab and colleagues were able to demonstrate.
3. Ceramide-3 is a component of the lipid matrix and can be incorporated into the epidermis, thus strengthening the skin barrier.

IGA Assessment: Assessment by the dermatologists



Conclusion

The excellent efficacy and tolerability of ALLERGIKA®-Facial Cream MED have been confirmed. The product is very well suited for the treatment of facial eczema and

relieves the symptoms of redness, scaling and skin dryness by 50% within only 7 days and by as much as 72% within 3 weeks.

Source: Used with kind permission of Prof. Dr. med. J. Ring



Characterisation and quantification of the protective effect of ALLERGIKA®-Facial Cream MED against exogenous noxae on healthy and artificially damaged skin

(Wohlrab et al. 2016, publication in preparation)




Study center	Institute for Applied Dermatopharmacy of the Martin Luther University Halle-Wittenberg
Head of Study	Prof. Dr. Johannes Wohlrab
Objective	The characterisation and quantification of the effects of the test product with regard to protection against exogenous noxae on healthy and artificially damaged skin
Target parameters	1. Transepidermal water loss over time 2. Water content in the stratum corneum (SC) over time
Implementation	1. Protective effect: Application of the test product, SLS application (irritation), removal of the SLS patch and measurement after 60, 120 and 180 min (not shown). 2. Regenerative effect: SLS application (irritation), single/multiple application of the test product, measurement after 60, 120, 240 min. (see fig.).
Study product	ALLERGIKA®-Facial Cream MED
Study design	Prospective, monocentric study with intraindividual comparison
Participants	27 male and female subjects between 20 and 37 years of age
Study period	1 day
Application area	Volar inner side of the forearms (6 test areas)

Results

1. Clear and relevant protective effect against exogenous irritant noxae (SLS) was confirmed
2. A barrier function deficit is completely prevented for several hours
3. Relevant regeneration effect after exposure to exogenous irritant noxae (see Figure)
4. The artificially induced barrier deficit is fully and sustainably compensated

Corneometry: Regeneration after SLS noxa



Conclusion

ALLERGIKA®-Facial Cream MED shows a rapid and long-lasting regeneration effect after barrier damage. The product is suitable for the treatment of atopic,

contact-allergic and irritant facial eczema. The protection of facial skin from the barrier-disrupting effect of exogenous, irritant noxae could be confirmed.



Source: Used with kind permission of Prof. Dr. med. J. Ring